Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

Saskia C. van der Boor, Merel Smit, Stijn W. van Beek, +19

The Lancet Infectious Diseases

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

Stijn W. van Beek, Rob ter Heine, Ron J. Keizer, +3

Clinical Pharmacokinetics

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Precious Ngwalero, James C.M. Brust, Stijn W. van Beek, +11

Antimicrobial Agents and Chemotherapy

Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

David W. Haas, Mahmoud Tareq Abdelwahab, Stijn W. van Beek, +11

The Journal of Infectious Diseases

A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept

Stan J. F. Hartman, Joost G. E. Swaving, Stijn W. van Beek, +5

Frontiers in Pharmacology

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Ralf Stemkens, Veronique de Jager, Rodney Dawson, +12

Antimicrobial Agents and Chemotherapy

Modeling the Impact of a Highly Potent <i>Plasmodium falciparum</i> Transmission-Blocking Monoclonal Antibody in Areas of Seasonal Malaria Transmission

Joseph D. Challenger, Stijn W. van Beek, Rob ter Heine, +9

The Journal of Infectious Diseases

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

Stijn W. van Beek, Rob ter Heine, Jan‐Willem C. Alffenaar, +3

Clinical Pharmacokinetics